Rebound increase in microRNA levels at the end of 5-FU-based therapy in colorectal cancer patients

Sci Rep. 2023 Aug 30;13(1):14237. doi: 10.1038/s41598-023-41030-7.

Abstract

Treatment with 5-fluorouracil (5-FU) based therapy is still used for colorectal cancer (CRC). Epigenetics has become a focus of study in cancer because of its reversibility besides its known regulatory functions. In this study, we will monitor the change in microRNAs (miRNAs) levels with 5-FU-based therapy at baseline and after 3 and 6 months of treatment to be correlated with their prognostic potential. The expression levels of 5 miRNAs, namely miRNA223-3p, miRNA20a-5p, miRNA17-5p, miRNA19a-3p, and miRNA7-5p, were measured in the peripheral blood of 77 CRC patients, along with the expression of 3 proteins PTEN, ERK, and EGFR. At baseline, CRC patients had significantly higher levels of circulating miRNAs than healthy controls. This level was reduced after 3 months of 5-FU-based therapy, then increased after 6 months significantly in responder patients compared to non-responders. MiRNA19a-3p showed that significant pattern of change in the subgroups of patients with high ERK, EGFR, and PTEN protein levels, and its 6 months level after 5-FU-based therapy showed significance for the hazard of increased risk of disease recurrence and progression.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Circulating MicroRNA*
  • Colorectal Neoplasms* / drug therapy
  • Colorectal Neoplasms* / genetics
  • ErbB Receptors / genetics
  • Fluorouracil / therapeutic use
  • Humans
  • MicroRNAs* / genetics

Substances

  • MicroRNAs
  • Circulating MicroRNA
  • Fluorouracil
  • ErbB Receptors
  • MIRN17 microRNA, human
  • MIRN7 microRNA, human